Suggested remit - To appraise the clinical and cost effectiveness of darolutamide within its marketing authorisation for treating non-metastatic hormone-relapsed prostate cancer.
Status In progress
Process STA 2018
ID number 1443

Provisional Schedule

Expected publication 25 November 2020

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
08 July 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of darolutamide for treating non-metastatic hormone-relapsed prostate cancer . Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-January 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
24 April 2019 - 23 May 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 May 2019 In progress, Referred 24 April 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance